PFTI, PPSI, UVIC, UMAM, TNLX, SMDM, LIQT
These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.
|StockGuru Spotlight||Symbol||Spotlight Price||High||Up As Much As||Market Cap|
|October 5, 2011||PLCSF||$0.115||$0.20||74%||$5.46M|
|October 26, 2011||CTIX||$0.34||$0.49||44%||$42.04M|
|October 14, 2011||ZORM||$0.22||$0.33||50%||$12.95M|
|September 20, 2011||GNBP||$0.98||$1.37||40%||$106.40M|
|October 28, 2011||MOJO||$0.27||$0.39||47%||$20.61M|
Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced on October 11, 2011, that it entered into a Patent License Agreement (the “License Agreement”) with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services (“NIH”). Pursuant to the License Agreement, NIH granted to the Company a non-exclusive worldwide license to 43 patents and patent applications, consisting of 9 issued United States patents, 13 United States patent applications, and 21 foreign corresponding patents and patent applications relating to adoptive cell therapy using autologous tumor infiltrating lymphocytes (TILs) for the treatment of certain cancers. The Company also has rights to sublicense the intellectual property subject to the terms and conditions set forth in the License Agreement. The License Agreement will expire on a product-by-product basis upon the expiration of the subject patent rights.
There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.
StockGuru is in its Ninth Year!